Key facts
- BioCatch’s last known valuation is $1.3B (Aug 2024).
- It has raised $239.3M; the latest was PE Growth/Expansion in Mar 2025.
- Notable investors include Sapphire Ventures, Macquarie Capital, Permira, Alanda Capital Management, Wyndham Wealth — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for BioCatch
- ·The full record, as it builds
Funding rounds
No funding rounds for BioCatch are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioCatch
Developer of behavioral biometrics and digital fraud detection software intended for financial institutions globally. The company uses machine learning models that analyze user interactions, such as keystroke patterns, mouse movements, touch screen behavior, device attributes, and transaction context to identify abnormal activity and help financial institutions detect fraud and financial crime during digital banking sessions.
- Sector
- Information Technology
- HQ
- Tel Aviv, Israel
- Founded
- 2011
- Employees
- 400
- Website
- biocatch.com/
- Ownership
- Privately Held (backing)
BioCatch doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioCatch shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioCatch in its N-PORT filings yet. We sweep new filings monthly.